Cytiva

ÄKTA readyflux™ filtration systems are fully automated tangential flow filtration (TFF) solutions that combine single-use flow kits and intuitive software to streamline bioprocessing workflows. Here’s what you can expect: No programming required Easily create and run methods with intuitive UNICORN™ softwa...

The Cytiva™ drug product filtration system operates using configurable recipe-controlled phases to automatically perform terminal sterilization prior to filling with maximum product recovery using standard flow kits. It has been designed to support EU GMP Annex 1: Manufacture of sterile medicinal products ...

The Cytiva™ manual drug product filtration system performs the sterile filtration of drug product. The system is designed to support the EU GMP Annex 1: Manufacture of sterile medicinal products by manually performing pre-use post sterilization integrity testing (PUPSIT) of the sterilizing-grade filters. ...

Enable small-batch flexibility and standardized manufacturing with this closed robotic isolator for pharmaceutical vial filling. Whether you’re making personalized medicines or clinical trial material, it’s built for agility and quick changeover. Flexible, scalable solution. Well-suited to filling a varie...

LevMixer™ systems feature a proprietary levitating impeller that enables gentle, scalable mixing for shear-sensitive applications with automation and data control across tank sizes from 10 to 1600 L. Designed for compatibility with single-use systems, the hardware is optimized for use in cGMP-compliant cle...

Cytiva helps the biopharma industry reduce Scope 3 emissions with strategies such as embedding ecodesign principles across our product portfolio and advancing process intensification approaches. Through the use of primary emissions data, we empower manufacturers to make smarter, data-driven sustainability decisions across the entire the value chain.

This presentation examines evolving therapeutic antibody processes. Processing of conventional mAbs continues to mature, while new chromatography approaches are required for multispecifics and fragments—as a one-size-fits-all strategy has become outdated. Optimizing capture requires selecting processes based on the target molecule, development stage, scale-up plans, and budgets. Moreover, antibody variants are challenged with aggregation and product-related impurities. We will evaluate strategies focused on resin selection, operation mode, and process conditions to boost purity, yield, and productivity, including new protein A resins.